All In Biotech

Drug Trial Radar · NCT06441682

A Safety and Efficacy Study of ARGX-119 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS)

A Phase 2a, Double-Blinded, Randomized, Placebo-Controlled, and Active-Treatment Extension Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of ARGX-119 in Participants With Amyotrophic Lateral Sclerosis

Last checked: Nov 19, 2026Latest source record: Sep 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

60

Actual

Start

Oct 23, 2024

Primary completion

Aug 12, 2026

Study completion Aug 12, 2026

Sponsor

Lead sponsor
argenxargenx (ARGX)
Sponsor type
Industry
First posted
Jun 4, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to evaluate the safety of ARGX-119 in adults with ALS. The study will also assess the impact of ARGX-119 on ALS disease outcomes, including muscle function. The study consists of 2 periods: a treatment period when participants will receive one of three ARGX-119 doses or placebo and an extension period when all participants will receive the same dose of ARGX-119. Participation in the study will last up to approximately 100 weeks.

Conditions

  • Amyotrophic Lateral Sclerosis

Interventions

  • ARGX-119Biological

    Intravenous infusion of ARGX-119

  • PlaceboOther

    Intravenous infusion of placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Assessment of adverse events (AEs)Time frame: Up to week 96

Locations

9 sites in 6 countries. Site status is shown where the registry gives one.

  • UZ Leuven

    Leuven, Belgium

  • Kaye Edmonton Clinic

    Edmonton, Canada

  • Montreal Neurological Institute and Hospital

    Montreal, Canada

  • Aarhus Universitets Hospital

    Aarhus, Denmark

  • Bispebjerg University Hospital

    Copenhagen, Denmark

  • Hôpital La Pitié Salpêtrière

    Paris, France

  • CHU Bretonneau

    Tours, France

  • UMC Utrecht

    Utrecht, Netherlands

  • Akademiskt specialistcentrum Karolinska Institutet

    Stockholm, Sweden

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.